CDKN2A and cancer: Previous studies have revealed that Bmi-1 interacts with a number of cancer-related signaling pathways, such as activating NF-κB signaling, suppressing the p16/Rb and/or p19ARF/MDM2/p53 tumor suppressive pathways, and inducing the activation of Hedgehog signaling [24]–[27].